| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net income | 392 | 232 | 87 | 864 |
| Depreciation | 110 | 70 | 34 | 132 |
| Amortization | 155 | 103 | 50 | 145 |
| Impairment of assets | 9 | 9 | - | - |
| Acquired in-process research and development and milestones | 6 | 6 | 6 | 81 |
| Fair value changes in contingent consideration | - | - | - | 11 |
| Accretion and changes in fair value in contingent consideration | 9 | -23 | -11 | - |
| Deferred income tax expense (benefit) | 33 | -7 | -17 | -160 |
| Stock-based compensation | 70 | 46 | 24 | 105 |
| Unrealized foreign exchange gain | 8 | -1 | 15 | 2 |
| Gain on debt repurchase | 46 | 46 | - | - |
| Other | -60 | -44 | -20 | -41 |
| Accounts receivable | 81 | 76 | 85 | -383 |
| Inventories | 94 | 31 | -3 | 131 |
| Other current assets | 54 | 78 | 11 | 236 |
| Trade accounts payable | -97 | -109 | -149 | -157 |
| Accrued and other current liabilities | 14 | -59 | 39 | -101 |
| Income taxes payable | -30 | 46 | 38 | -65 |
| Other | -129 | -121 | -40 | -29 |
| Net cash flows provided by operating activities | 559 | 295 | 75 | 939 |
| Capital expenditures | 117 | 71 | 32 | 175 |
| Proceeds from sale of property, plant and equipment | 1 | 1 | - | 4 |
| Acquired in-process research and development and milestones | 10 | 10 | 10 | 71 |
| Dermavant acquisition, net of cash acquired | 75 | 75 | 75 | 166 |
| Purchase of product rights and asset acquisition | 124 | 55 | 55 | 105 |
| Net cash flows used in investing activities | -325 | -210 | -172 | -513 |
| Proceeds from debt | 730 | 430 | 90 | 1,186 |
| Repayments of debt | 1,006 | 634 | 93 | 1,197 |
| Payment of long-term debt issuance costs | 0 | 0 | - | 38 |
| Employee withholding taxes related to stock-based awards | 14 | 13 | 1 | 22 |
| Dividend payments | 84 | 81 | 71 | 297 |
| Net cash flows used in financing activities | -374 | -298 | -75 | -368 |
| Effect of exchange rate changes on cash and cash equivalents | 137 | 137 | 44 | -76 |
| Net (decrease) increase in cash and cash equivalents | -3 | -76 | -128 | -18 |
| Cash and cash equivalents at beginning of period | 675 | 675 | 675 | 693 |
| Cash and cash equivalents at end of period | 672 | 599 | 547 | 675 |
Organon & Co. (OGN)
Organon & Co. (OGN)